Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding GRID2-related autosomal dominant spinocerebellar ataxia is primarily due to its rarity, affecting fewer than 1 in 100,000 individuals. This extreme rarity makes systematic clinical studies challenging, resulting in a lack of comprehensive data on its genetic basis and clinical features. Ongoing research may eventually provide clearer insights into this condition.
To navigate your care effectively, seek a neurologist with expertise in hereditary ataxias. They can provide specialized insights into your condition and potential management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participation in clinical trials may also be an option, and you can find relevant studies at ClinicalTrials.gov. Genetic counseling may be beneficial to discuss any potential hereditary implications.
There are several orphan drugs currently designated for GRID2-related autosomal dominant spinocerebellar ataxia, including (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and 4-aminopyridine (4-AP). Additionally, there is one active clinical trial available for this condition. For more information on ongoing research, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=GRID2-related%20autosomal%20dominant%20spinocerebellar%20ataxia.
Actionable guidance for navigating care for GRID2-related autosomal dominant spinocerebellar ataxia
To navigate your care effectively, seek a neurologist with expertise in hereditary ataxias. They can provide specialized insights into your condition and potential management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participation in clinical trials may also be an option, and you can find relevant studies at ClinicalTrials.gov. Genetic counseling may be beneficial to discuss any potential hereditary implications.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding GRID2-related autosomal dominant spinocerebellar ataxia is primarily due to its rarity, affecting fewer than 1 in 100,000 individuals. This extreme rarity makes systematic clinical studies challenging, resulting in a lack of comprehensive data on its genetic basis and clinical features. Ongoing research may eventually provide clearer insights into this condition.
To navigate your care effectively, seek a neurologist with expertise in hereditary ataxias. They can provide specialized insights into your condition and potential management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participation in clinical trials may also be an option, and you can find relevant studies at ClinicalTrials.gov. Genetic counseling may be beneficial to discuss any potential hereditary implications.
There are several orphan drugs currently designated for GRID2-related autosomal dominant spinocerebellar ataxia, including (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and 4-aminopyridine (4-AP). Additionally, there is one active clinical trial available for this condition. For more information on ongoing research, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=GRID2-related%20autosomal%20dominant%20spinocerebellar%20ataxia.
Actionable guidance for navigating care for GRID2-related autosomal dominant spinocerebellar ataxia
To navigate your care effectively, seek a neurologist with expertise in hereditary ataxias. They can provide specialized insights into your condition and potential management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participation in clinical trials may also be an option, and you can find relevant studies at ClinicalTrials.gov. Genetic counseling may be beneficial to discuss any potential hereditary implications.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding GRID2-related autosomal dominant spinocerebellar ataxia is primarily due to its rarity, affecting fewer than 1 in 100,000 individuals. This extreme rarity makes systematic clinical studies challenging, resulting in a lack of comprehensive data on its genetic basis and clinical features. Ongoing research may eventually provide clearer insights into this condition.
To navigate your care effectively, seek a neurologist with expertise in hereditary ataxias. They can provide specialized insights into your condition and potential management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participation in clinical trials may also be an option, and you can find relevant studies at ClinicalTrials.gov. Genetic counseling may be beneficial to discuss any potential hereditary implications.
There are several orphan drugs currently designated for GRID2-related autosomal dominant spinocerebellar ataxia, including (1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and 4-aminopyridine (4-AP). Additionally, there is one active clinical trial available for this condition. For more information on ongoing research, you can visit the ClinicalTrials.gov search page: https://clinicaltrials.gov/search?cond=GRID2-related%20autosomal%20dominant%20spinocerebellar%20ataxia.
Actionable guidance for navigating care for GRID2-related autosomal dominant spinocerebellar ataxia
To navigate your care effectively, seek a neurologist with expertise in hereditary ataxias. They can provide specialized insights into your condition and potential management strategies. Additionally, consider exploring resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participation in clinical trials may also be an option, and you can find relevant studies at ClinicalTrials.gov. Genetic counseling may be beneficial to discuss any potential hereditary implications.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.